Brief: Protagonist Therapeutics Inc - QTRLY Loss Per Share $0.84
04/08/2022 22:22
Protagonist Therapeutics Inc PTGX.O :
* PROTAGONIST REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
AND
PROVIDES CORPORATE UPDATE
* STRONG CASH POSITION, WITH CASH RUNWAY THROUGH END OF 2024
* QTRLY LOSS PER SHARE $0.84
* Q2 EARNINGS PER SHARE VIEW $-0.93 -- REFINITIV IBES DATA
Source text for Eikon: ID:nPn6kW5R6a
Further company coverage: PTGX.O
Recent news on Protagonist Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary